26 Oct 2023
T-PASS: Less than 1-month DAPT followed by ticagrelor monotherapy after DES Implantation for ACS
Reported from TCT 2023
Ali Nazmi Calik interviews Myeong-Ki Hong about the results of the T-Pass randomised trial which he presented during the #TCT Congress 2023 in San Francisco.
The study provides evidence that stopping aspirin within 1 month for ticagrelor monotherapy is both non-inferior and superior to 12-month DAPT as for the 1-year composite outcome of death, myocardial infarction, stent thrombosis, stroke, and major bleeding.
Authors
1 comment
In my opinion with regard to increased risk for bleeding in Asian patients the result of this study is very important